PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters-Reference-Cited by-同舟云学术

PBPK Modeling of the Effect of Reduced Kidney Function on the Pharmacokinetics of Drugs Excreted Renally by Organic Anion Transporters

Published:2017-07-24 Issue:3 Volume:103 Page:485-492
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Hsueh C-H¹²³,Hsu V²,Zhao P²,Zhang L²,Giacomini KM¹,Huang S-M²

Affiliation:

1. Department of Bioengineering and Therapeutic Sciences; University of California San Francisco; San Francisco California USA

2. Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research; US Food and Drug Administration; Silver Spring Maryland USA

3. Oak Ridge Institute for Science and Education (ORISE) Fellow; Oak Ridge Tennessee USA

Funder

Food and Drug Administration (FDA)

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Reference49 articles.

1. Renal transporters in drug development;Morrissey;Annu. Rev. Pharmacol. Toxicol.,2013

2. United States Renal Data System 2015 United States Renal Data System Annual Data Report: Epidemiology of Kidney Disease in the United States 2015

3. The pathologic physiology of chronic Bright's disease. An exposition of the “intact nephron hypothesis;Bricker;Am. J. Med.,1960

4. On the meaning of the intact nephron hypothesis;Bricker;Am. J. Med.,1969

5. Pharmacokinetics and dosage adjustment in patients with renal dysfunction;Verbeeck;Eur. J. Clin. Pharmacol.,2009

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PRT to predict pharmacokinetic profiles as part of a bioequivalence study of the drug deferasirox;Drug development & registration;2024-08-27

2. Advancing precision medicine therapeutics for Parkinson’s utilizing a shared quantitative systems pharmacology model and framework;Frontiers in Systems Biology;2024-03-08

3. Simultaneously Predicting the Pharmacokinetics of CES1-Metabolized Drugs and Their Metabolites Using Physiologically Based Pharmacokinetic Model in Cirrhosis Subjects;Pharmaceutics;2024-02-05

4. Chronic kidney disease and physiologically based pharmacokinetic modeling: a critical review of existing models;Expert Opinion on Drug Metabolism & Toxicology;2024-01-31

5. Regulatory Requirements and Applications of Physiologically Based Pharmacokinetic Models;ADME Processes in Pharmaceutical Sciences;2024